Latest News & Features
Big Pharma
At first glance, it might seem odd for a company to both divide blood plasma and fight the side-effects of cancer treatment. But not for PlasmaTech Biopharmaceuticals, which tells LSIPR about how the company does it and also protects its IP. 26 November 2014
Big Pharma
A new EU policy will require pharmaceutical companies to provide clinical trial data when seeking marketing approval for their drugs. But how will they ensure adequate IP protection while embracing the new culture of transparency? LSIPR reports. 25 November 2014
Biotechnology
Earlier this year, the Advocate General of
the CJEU opined that stem cells from parthenotes are patentable. Franz-Josef Zimmer and Markus Grammel examine the reasoning behind his opinion. 4 November 2014
Americas
Protecting rights related to desirable plant species is a delicate process, says Gabriel Di Blasi. 4 November 2014
Big Pharma
Depositing a microorganism in a country may be crucial for obtaining a method patent in that jurisdiction, but can come with its pitfalls, says Peter ten Haaft. 4 November 2014
Europe
Dennis Waller discusses how differing interpretations of the Bolar exemption may affect clinical trials in the UK. 3 November 2014
Europe
Richard Bassett and Richard Wells look at what EU-based companies must consider in order to comply with the Nagoya Protocol, the regulation aimed at curbing biopiracy. 3 November 2014
Americas
Who has legal interest in the grant of sanitary registrations for follow-on biologics? José Trigueros examines a recent case in Mexico that could have far-reaching ramifications. 3 November 2014
Americas
Jason Rutt considers the impact AstraZeneca’s recent US pay-for-delay case will have on the industry. 3 November 2014
Big Pharma
The current outbreak of Ebola has devastated communities in West Africa. It has also thrown a light on the complex web of IP rights surrounding the possible treatments for this serious and usually fatal virus, as LSIPR discovered. 3 November 2014